Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
OwnerVirginia L. Smith-Swintoskyinventor
Life of this patent
Estimating the term…
Abstract
The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is directed to a method for the treatment of depression, which includes mono-therapy and alternatively, co-therapy with at least one antidepressant.
Claims29
A method of treating depression comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, trifluoromethyl, nitro and cyano;
- X—Y is selected from the group consisting of —S—CH—, —S—C(CH3)—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;
- A is selected from the group consisting of —CH2— and —CH(CH3)—;
- R2 is selected from the group consisting of hydrogen and methyl;
- R3 and R4 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
- alternatively, R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;
- or a pharmaceutically acceptable salt thereof.
A method of treating depression comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of N-(benzo[b]thien-3-ylmethyl)-sulfamide and pharmaceutically acceptable salts thereof.
A method for the treatment of depression comprising administering to a subject in need thereof co-therapy with a therapeutically effective amount of at least one antidepressant and a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, trifluoromethyl, nitro and cyano;
- X—Y is selected from the group consisting of —S—CH—, —S—C(CH3)—, —O—CH—, —O—C(CH3)—, —N(CH3)—CH— and —CH═CH—CH—;
- A is selected from the group consisting of —CH2— and —CH(CH3)—;
- R2 is selected from the group consisting of hydrogen and methyl;
- R3 and R4 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
- alternatively, R3 and R4 are taken together with the nitrogen atom to which they are bound to form a 5 to 7 membered, saturated, partially unsaturated or aromatic ring structure, optionally containing one to two additional heteroatoms independently selected from the group consisting of O, N and S;
- or a pharmaceutically acceptable salt thereof.
A method for the treatment of depression comprising administering to a subject in need thereof co-therapy with a therapeutically effective amount of at least one antidepressant and a compound selected from the group consisting N-(benzo[b]thien-3-ylmethyl)-sulfamide;
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.